NEW YORK (GenomeWeb) – ERS Genomics said today that it has signed a non-exclusive license agreement for its CRISPR-Cas9 patents with Charles River Laboratories.

Charles River, which uses CRISPR-Cas9 for target screening and to create custom knock-in and knockout cell lines for drug discovery applications, said it will use the license to offer its customers a larger range of in vivo and in vitro genome editing services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.